← All trials
NCT06217302
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2024
- Primary completion
- Dec 31, 2028
- Completion date
- May 31, 2029
- First posted
- Jan 22, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Joslin Diabetes CenterLead sponsor
- Joslin Diabetes CenterCollaborator
- The Kidney Foundation of CanadaCollaborator
- University of TorontoCollaborator
- University of Colorado, DenverCollaborator
- University of MinnesotaOfficial
- University of TorontoCollaborator
- DexCom, Inc.Collaborator
- Joslin Diabetes CenterOfficial
- University of AlbertaCollaborator
- University of MichiganCollaborator
- University of TorontoOfficial
- State University of New York, SyracuseCollaborator
- The Cleveland ClinicCollaborator
- University of WashingtonCollaborator
- Stanford UniversityCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Northwestern UniversityCollaborator
- McGill UniversityCollaborator
- Washington University in St. LouisCollaborator
- Joslin Diabetes CenterSponsor investigator
- LMC Diabetes & Endocrinology Ltd.Collaborator
- University of CalgaryCollaborator
- University of British ColumbiaCollaborator
- Yeshiva UniversityCollaborator
- Lexicon PharmaceuticalsCollaborator
- Breakthrough T1DCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.